After Roivant Sciences (ROIV) announced results from the induction period of the TUSCANY-2 Phase 2b study of RVT-3101, Piper Sandler analyst Yasmeen Rahimi argued that the readout further validates the TL1A mechanism in ulcerative colitis, or UC. Her comparative analysis of Prometheus Biosciences’ (RXDX) ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a study results and the TUSCANY induction data lead her to believe Prometheus’ PRA023 and Roivant’s RVT-3101 have "highly competitive profiles," said Rahimi, who keeps an Overweight rating and $114 price target on Prometheus shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RXDX:
- Prometheus Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Biotech Alert: Searches spiking for these stocks today
- Prometheus (NASDAQ:RXDX) Stock: Here’s What Caused the Electrifying Rally
- Prometheus 4.55M share Secondary priced at $110.00
- Prometheus Biosciences, Inc. Announces Pricing of Public Upsized $500 Million Offering of Common Stock